Kurapa kweBrexu-cel CAR-T Kunoratidza Mhedzisiro Inofadza muVarwere Vakuru Vanoongorora Varwere Vese
Brexucabtagene autoleucel (brexu-cel), mushonga weCD19 CAR-T cell therapy, wave mushonga unokosha wekurapa relapse/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) muvanhu vakuru. Zvichibva pamhedzisiro yeZUMA-3 test, brexu-cel yakagamuchirwa muUnited States kuvarwere vakuru vane R/R B-ALL. Zvisinei, zvidzidzo zvepanyika zvakakosha kuti tinzwisise zvizere kushanda kwayo uye kuchengetedzeka kwayo mukurapa. Chidzidzo chikuru chakabudiswa munguva pfupi yapfuura mu Chinyorwa cheClinical Oncology inopa ruzivo rwakakosha pamusoro pekushanda kwebrexu-cel muboka guru revarwere, zvichiratidza mhedzisiro inokurudzira muhuwandu hwekurerukirwa uye kupona.
Pfupiso Yekudzidza
Chidzidzo ichi chakaitwa munzvimbo dzakasiyana-siyana chaisanganisira varwere vakuru 204 vane R/R B-ALL avo vakarapwa kunze kwemiedzo yekiriniki munzvimbo 31 dzekurapa muUnited States. Varwere vese 189 vakabudirira kugamuchira brexu-cel, nepakati pemitsetse mina yekurapwa yapfuura. Vanenge hafu yevarwere vakamboitwa hematopoietic stem cell transplantation (HSCT), 59% vakange vagamuchira blinatumomab, uye 48% vakange varapwa neinotuzumab ozogamicin. Panguva ye leukapheresis, 42% yevarwere vaive mu morphological relieve, chiyero chaizove chakavabvisa muongororo yekutanga yeZUMA-3.
Zvakawanikwa Zvikuru
Mushure mekutevera kwepakati pemwedzi 11.4, mhedzisiro yekudzidza yakaratidza kushanda kwakasimba kwebrexu-cel mukurapa R/R B-ALL:
- Mhinduro Yakazara (CR): 90% yevarwere vakarapwa vakapindura zvizere, 79% vachiratidza kuregererwa kushoma kwechirwere (MRD)-negative.
- Kupona Kusina Kufambira Mberi (PFS): PFS yepakati yaive mwedzi 9.5.
- Kupona Kwese (OS): Kushanda kwepakati (Median OS) hakuna kuwanikwa, zvichiratidza kuti zvinogona kuramba kwenguva refu mukuwedzera nguva yekurarama kwemurwere.
- Kusagadzikana kweMRD: Kune varwere vane MRD yakaongororwa vachishandisa cloneSEQ next-generation sequencing, MRD negativity pazuva rechi28 yakabatana nekuvandudzwa kwePFS neOS, zvichisimbisa kukosha kweMRD sechiratidzo chekufanotaura.
Mhedzisiro yeKurapa Kwekubatanidza
Chidzidzo ichi chakaenderera mberi chichiratidza kuti varwere vakagamuchira consolidative HSCT mushure mekurapwa nebrexu-cel vaive nePFS iri nani zvikuru kana tichienzanisa nevaya vasina kupihwa consolidation kana maintenance therapy. Muongororo ye multivariate, HSCT (yakaitwa muvarwere makumi matatu) post-CAR-T therapy yakabatana nekudzikira kwakanyanya kwengozi yekufambira mberi kwechirwere (HR=0.34).
Nhoroondo Yekuchengetedza
Pasinei nekushanda kwayo, kurapwa kwebrexu-cel kwakaratidza matambudziko makuru, ayo ari matanho akakosha ekutarisira kurapwa:
- Cytokine Release Syndrome (CRS) uye Neurotoxicity (ICANS): CRS yakataurwa mu84% yevarwere, vane zviitiko zvakakomba (giredhi 3-4) mu11%. ICANS yakaitika mu56% yevarwere, uye zviitiko zvakakomba mu31%.
- Rufu uye Kusadzokera Kurufu: Makumi matatu nemana muzana evarwere vakafa panguva yekudzidza uku, ne13% yevakafa vasina chekuita nekukura kwechirwere chemukondombera. Varwere gumi vakafa mukati memazuva makumi maviri nemasere ekutanga mushure mekurapwa nekuda kwechepfu kana hutachiona, kunyanya pakati pevaya vane dambudziko guru rezvirwere. Utachiona hwefungus ndihwo hwainyanya kukonzera kufa kunokonzerwa nehutachiona, zvichiratidza kuti panofanira kutariswa hutachiona nekungwarira.
Mhedziso
Zvakawanikwa muchidzidzo ichi chechokwadi zvinoenderana nezvakabuda muongororo yeZUMA-3, zvichisimbisa huwandu hwakanyanya hweMRD-negative CR muBrexu-cel uye mhedzisiro yakanaka yekurarama kwevarwere vakuru vane R/R B-ALL. Zvisinei, chepfu dzakakura, kunyanya ICANS dzakakomba uye kufa kwekutanga, zvinoratidza kukosha kwenzira dzekuderedza njodzi, kusanganisira kudzivirira hutachiona uye kutarisa zvakanyanya. Pamusoro pezvo, kushandiswa kwemishonga yeHSCT post-CAR-T kwakaratidzwa kuvandudza kurarama pasina kufambira mberi, zvichipa nzira inogona kugadzirisa mhedzisiro yemurwere.
Chidzidzo ichi chinosimbisa basa rebrexu-cel senzira yakajairika yekurapa R/R B-ALL yevakuru ukuwo ichisimbisa matambudziko aripo mukugadzirisa migumisiro yayo yakaipa.